CTHRC1 is associated with BRAF (V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma.

MLA

Zhang, Rumeng, et al. “CTHRC1 Is Associated with BRAF (V600E) Mutation and Correlates with Prognosis, Immune Cell Infiltration, and Drug Resistance in Colon Cancer, Thyroid Cancer, and Melanoma.” Biomolecules & Biomedicine, July 2024. EBSCOhost, https://doi.org/10.17305/bb.2024.10397.

APA

Zhang, R., Wang, Z., Wang, H., Li, L., Dong, L., Ding, L., Li, Q., Zhu, L., Zhang, T., Zhu, Y., & Ding, K. (2024). CTHRC1 is associated with BRAF (V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomolecules & Biomedicine. https://doi.org/10.17305/bb.2024.10397

Chicago

Zhang, Rumeng, Zhihao Wang, Huan Wang, Lin Li, Lin Dong, Lin Ding, Qiushuang Li, et al. 2024. “CTHRC1 Is Associated with BRAF (V600E) Mutation and Correlates with Prognosis, Immune Cell Infiltration, and Drug Resistance in Colon Cancer, Thyroid Cancer, and Melanoma.” Biomolecules & Biomedicine, July. doi:10.17305/bb.2024.10397.